Measles containing vaccines comparison
ExportBiological E. Limited
Microgen
POLYVAC
PT Bio Farma Persero
Razi Vaccine & Serum Research Institute
Serum Institute of India / SII
Takeda
Zydus Lifesciences Limited
Beijing Institute of Biological Products Co., Ltd.
Bio-Manguinhos/Fiocruz
Serum Institute of India Pvt. Ltd.
GlaxoSmithKline Biologicals SA
Merck Sharp & Dohme LLC
Microgen
Razi Vaccine & Serum Research Institute
Shanghai Institute of Biological Products Co.,Ltd
Zydus Lifesciences Limited
Zydus Lifesciences Limited. Measles Vaccine (Live) I.P. (Freeze Dried): summary of product characteristics. New Delhi: Central Drugs Standard Control Organization; 2024. (https://www.cdsco.gov.in/opencms/opencms/en/biologicals/Vaccines, accessed 23 August
Serum Institute of India Pvt. Ltd.
Beijing Institute of Biological Products Co
Beijing Minhai Biotec Group
Bio-Manguinhos/Fiocruz
Biken
Daiichi Sankyo Biotec
POLYVAC
Razi Vaccine & Serum Research Institute
Takeda
Zydus Lifesciences Limited
Central Drugs Standard Control Organization, India
Ministry of Health of the Russian Federation
National Regulatory Authority of Vietnam
National Agency of Drug and Food Control of Indonesia (Badan POM).
Food and Drug Administration of the Ministry of Health and Medical Education, Iran
Central Drugs Standard Control Organization, Ministry of Health and Family Welfare, India.
Ministry of Health, Labour and Welfare, Japan
Central Drugs Standard Control Organization, Ministry of Health and Family Welfare, India.
National Medical Products Administration, China
Brazilian Health Regulatory Agency
Central Drugs Standard Control Organization, India
Federal Agency for Medicines and Health Products
European Medicines Agency
Ministry of Health of the Russian Federation
Food and Drug Administration of the Ministry of Health and Medical Education, Iran
National Medical Products Administration, China
Central Drugs Standard Control Organization, Ministry of Health and Family Welfare, India
Central Drugs Standard Control Organization, Ministry of Health and Family Welfare, India.
Central Drugs Standard Control Organization, Ministry of Health and Family Welfare, India.
National Medical Products Administration, China
National Medical Products Administration, China
Brazilian Health Regulatory Agency
Ministry of Health, Labour and Welfare, Japan, with regulatory review through Pharmaceutical and Medical Device Agency
Ministry of Health, Labour and Welfare, Japan, with regulatory review through Pharmaceutical and Medical Device Agency
National Regulatory Authority of Vietnam
Food and Drug Administration of the Ministry of Health and Medical Education, Iran
Ministry of Health, Labour and Welfare, Japan, with regulatory review through Pharmaceutical and Medical Device Agency
Central Drugs Standard Control Organization, Ministry of Health and Family Welfare, India
2021
1960
2009
1997
1984
1991
1978
2016
2002
N/A
1990
1997
2006
2019
2003
2007
2016
2017
1989
2002
2012
2022
2005
2011
2017
1987
2005
2018
2026
N/A
N/A
10-dose:1997 20-dose: 2006
N/A
1993
N/A
N/A
N/A
N/A
2003
1-dose: 2001 2-dose: 2011
2009
N/A
N/A
N/A
N/A
2019
2000
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Live attenuated measles virus: CAM-70 (Tanabe) strain
Live attenuated measles virus: Leningrad-16 (L-16) or Moscow-5 strain
Live attenuated measles virus: AIK-C strain
Live, attenuated measles virus: CAM-70 or Edmonston-Zagreb strain
Live attenuated measles virus: AIK-C strain
Live, attenuated measles virus: Edmonston-Zagreb strain
Live, attenuated measles virus: Schwarz FF-8 strain
Live, attenuated measles virus: Edmonston-Zagreb strain
Live attenuated viruses: measles: Hu-191strain; mumps: S79 strain; rubella: BRD II strain
Live attenuated viruses: measles: Schwarz strain; mumps: RIT 4385 strain (derived from Jeryl Lynn); Rubella: Wistar RA27/3 strain
Live attenuated viruses: measles: Edmonston-Zagreb strain; mumps: Leningrad-Zagreb strain; Rubella: Wistar RA27/3 strain
Live attenuated viruses: measles: Schwarz strain; mumps: RIT 4385 strain (derived from Jeryl Lynn); Rubella: Wistar RA27/3 strain
Live attenuated viruses: measles: Enders' Edmonston strain; mumps: Jeryl Lynn level B strain; Rubella: Wistar RA27/3 strain
Live attenuated viruses: measles: Leningrad-16 strain;
mumps: Leningrad-3 strain; rubella: Wistar RA 27/3 strain
Live attenuated viruses: measles: AIK-C strain; mumps: RS-12 strain; rubella: Takahashi strain
Live attenuated viruses: measles: Hu-191 strain; mumps: S79 strain; rubella: BRD II lstrain
Live attenuated viruses: measles: Edmonston-Zagreb strain; mumps: Hoshino strain; Rubella: RA27/3 strain
Live attenuated viruses: measles: CAM-70 strain; rubella: Wistar RA 27/3 strain
Live attenuated viruses: measles: Edmonston-Zagreb strain; rubella: Wistar RA 27/3 strain
Live attenuated viruses: measles: Hu-191 strain; rubella: BRD II strain
Live attenuated viruses: measles: Chang-47 strain. rubella: RA27/3 strain
Live attenuated viruses: measles: Schwarz strain; rubella: Wistar RA 27/3 strain
Live attenuated viruses: measles: Tanabe strain; rubella: Matsuura strain
Live attenuated viruses: measles: AIK-C strain; rubella: Takahashi strain
Live attenuated viruses: measles: AIK-C strain; rubella: Takahashi strain
Live attenuated viruses: measles: AIK-C strain; rubella: - Takahashi strain
Live attenuated viruses: measles: Schwarz FF-8 strain; rubella: TO-336 strain
Live attenuated viruses: measles: Edmonston-Zagreb; rubella: Wistar RA 27/3 strain
Chicken embryo fibroblast cells
Japanese quail embryo cell cultures
Chick embryo fibroblast cells
Chicken embryo fibroblast cells or human diploid cells
Human diploid cells (MRC-5) or chick embryo fibroblasts
Human diploid cells (MRC-5)
Chick embryo cells
Human diploid cells (MRC-5)
Measles: primary chicken embryo cells; mumps: primary chicken embryo cells; rubella: human diploid cells
Measles: primary chicken embryo cells; mumps: primary chicken embryo cells; rubella: human diploid cells (MRC-5)
N/A
N/A
N/A
Japanese quail embryonic fibroblast cell cultures
Human diploid cells (MRC-5)
Measles: primary chicken embryo cells; mumps: primary chicken embryo cells; rubella: human diploid cells
Measles: human diploid/MRC-5 cells; Mumps: chick fibroblast cells; Rubella: human diploid cells
Measles: chicken embryo fibroblast cells; rubella: human diploid cells (MRC-5)
Human diploid cells
Measles: primary chicken embryo cells; rubella: human diploid cells
Measles: primary chicken embryo cells; rubella: human diploid cells (MRC-5)
Measles: chick embryo cells; rubella: human diploid cells
Measles: chicken embryo cells; rubella: quail embryo cells
Measles: SPF chicken embryo cells; Rubella: SPF rabbit kidney cells.
Measles: SPF chicken embryo cells; Rubella: SPF rabbit kidney cells.
Human diploid cells (MRC-5)
Chick embryo cells
Human diploid cells (MRC-5)
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
Reconstitute using the supplied 0.9% w/v sodium chloride injection diluent
Reconstitute using 0.9% sodium chloride or specialized sterile water-for-injection diluent
Reconstitute using sterile water-for-injection diluent provided by manufacturer
Reconstitute using sterile water-for-injection diluent provided by manufacturer
Reconstitute using 0.9% sodium chloride or specialized sterile water-for-injection diluent
Reconstitute using 0.9% sodium chloride or specialized sterile water-for-injection diluent
Reconstitute using sterile water-for-injection diluent supplied explicitly by manufacturer
Reconstitute using sterile water-for-injection diluent
Reconstitute using sterile water-for-injection diluent supplied by manufacturer
Reconstitute using sterile water-for-injection diluent supplied by manufacturer
Reconstitute using sterile water-for-injection diluent
Reconstitute using sterile water-for-injection diluent
Reconstitute using sterile water-for-injection diluent
Reconstitute using sterile water-for-injection diluent supplied by manufacturer
Reconstitute using sterile water-for-injection or 0.9% sodium chloride diluents supplied by manufacturer
Reconstitute using sterile water-for-injection diluent supplied by manufacturer
Reconstitute using sterile water-for-injection diluent supplied by manufacturer
Reconstitute with 0.9% sodium chloride diluent
Reconstitute with water-for-injection
Reconstitute with water-for-injection supplied by manufacturer
Reconstitute with water-for-injection supplied by manufacturer
Reconstitute with water-for-injection
Reconstitute using sterile water-for-injection diluent supplied by manufacturer
Reconstitute using sterile water-for-injection diluent supplied by manufacturer
Reconstitute using sterile water-for-injection diluent supplied by manufacturer
Reconstitute using sterile water-for-injection or 0.9% sodium chloride diluents supplied by manufacturer
Reconstitute using sterile water-for-injection diluent supplied by manufacturer
Reconstitute using sterile water-for-injection diluent supplied by manufacturer
Lyophilised active component to be reconstituted with excipient diluent before use
Lyophilized (freeze-dried)
Lyophilized (freeze-dried)
Lyophilized (freeze-dried)
Lyophilized (freeze-dried)
Lyophilized (freeze-dried)
Lyophilized (freeze-dried)
Lyophilized (freeze-dried)
Lyophilized (freeze-dried)
Lyophilized (freeze-dried)
Lyophilized (freeze-dried)
Lyophilized (freeze-dried)
Lyophilized (freeze-dried)
Lyophilized (freeze-dried)
Lyophilized (freeze-dried)
Lyophilized (freeze-dried)
Lyophilized (freeze-dried)
Lyophilized (freeze-dried)
Lyophilized (freeze-dried)
Lyophilized (freeze-dried)
Lyophilized (freeze-dried)
Lyophilized (freeze-dried)
Lyophilized (freeze-dried)
Lyophilized (freeze-dried)
Lyophilized (freeze-dried)
Lyophilized (freeze-dried)
Lyophilized (freeze-dried)
Lyophilized (freeze-dried)
5-dose vial
10-dose vial
1-dose vial
5-dose vial
10-dose vial with diluent
10-dose vial with diluent ampoule
20-dose vial with diluent ampoule
1-dose vial
5-dose vial
1-dose vial
2-dose vial
5-dose vial
10-dose vial
1-dose vial
1-dose vial
10-dose vial
1-dose vial with diluent ampoule
10-dose vial with diluent ampoule
1-dose vial
2-dose vial
5-dose vial
10-dose vial
1-dose vial
2-dose vial
1-dose vial
1-dose vial and diluent ampoule
1-dose vial
2-dose vial
5-dose vial
1-dose vial and diluent syringe
1-dose vial
10-dose vial
1-dose vial + ampoule
5-dose vial + ampoule
10-dose vial + ampoule
1-dose vial
2-dose vial
5-dose vial
10-dose vial; diluent supplied in ampoules
1-dose vial
1-dose vial and diluent ampoule
10-dose vial
1-dose vial
1-dose vial with diluent
10-dose vial with diluent
1-dose vial
5-dose vial
1-dose vial
1-dose vial
5-dose vial
10-dose vial
Subcutaneous
Subcutaneous
Subcutaneous
Subcutaneous
Subcutaneous
Subcutaneous
Subcutaneous
Subcutaneous
Subcutaneous
Subcutaneous
Subcutaneous
Intramuscular or subcutaneous
Intramuscular
Subcutaneous or intramuscular
Subcutaneous
Subcutaneous
Subcutaneous
Subcutaneous
Subcutaneous
Subcutaneous
Subcutaneous
Subcutaneous
Subcutaneous
Subcutaneous
Subcutaneous
Subcutaneous
Subcutaneous
Subcutaneous
24 months
24 months
24 months
36 months
24 months
24 months
12 - 24 months
24 months
18 months
24 months
30 months
24 months
24 months
24 months
24 months
N/A
24 months 1-dose; 12 months 10-dose
30 months
30 months
24 months
18 months
30 months
12 months
18 months
24 months
24 months
12 – 24 months
24 months
2–8 °C
2–8 °C
2–8 °C
2–8 °C
2–8 °C
2–8 °C
2–8 °C
2–8 °C
2–8°C
2–8°C
2–8°C
2–8°C
2–8°C
2–8°C
2–8°C
2–8°C
2–8°C
2–8 °C
2–8 °C
2–8 °C
2–8 °C
2–8 °C
≤5°C
≤5°C
2–8 °C
2–8 °C
2–8 °C
2–8 °C
Type 14
N/A
N/A
Type 14
N/A
Type 14
N/A
N/A
N/A
N/A
Type 14
Type 7
Type 7
N/A
N/A
N/A
N/A
Type 14
Type 14
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Carton of 50 vials (250 doses).
Dimensions: 16.5 x 9.0 x 4.5 cm
N/A
N/A
Active: 3.3 Diluent: 2.53 cm3/dose (in secondary packaging)
N/A
1.78 cm³ per dose inside secondary multi-dose packaging formats
N/A
N/A
N/A
N/A
1-dose: vial: 21.09; diluent ampoule: 12.528 cm³/dose;
5-dose: vial: 10.545; diluent ampoule: 6.264 cm³/dose;
10-dose: vial: 4.218; diluent ampoule: 5.481 cm³/dose
1-dose: vial: 9.29; diluent ampoule: 20.23 cm³/dose; 2-dose: vial: 4.8; diluent ampoule: 13.11 cm³/dose
15 cm³/dose
Varies by presentation pack (typically estimated at 30–40 cm³ per single-dose combination kit including the corresponding diluent ampoule package).
N/A
N/A
N/A
1-dose: active 14.09 + diluent 7.80 cm³/dose; 5-dose: active 2.67 + diluent 3.25 cm³/dose; 10-dose: active 1.78 + diluent 2.12 cm³/dose
1-dose: vial 21.09 + diluent 12.528 cm³/dose; 2-dose: vial 10.545 + diluent 6.264; 5-dose: vial 4.218 + diluent 5.481; 10-dose: vial 2.109 + diluent 3.1424 cm³/dose
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Standard: 9 months or shortly thereafter. Where measles infection occurs later: 12–15 months.
Second dose may be given as early as one month after the first dose.
Standard: 9 months + 15–18 months. Low measles transmission: 12–15 months + second dose according to national schedule.
Standard: 9 months + 15–18 months. Low measles transmission: 12–15 months + second dose according to national schedule.
Standard: 9 months + 15–18 months. Low measles transmission: 12–15 months + second dose according to national schedule.
Standard: 9 months + 15–18 months. Low measles transmission: 12–15 months + second dose according to national schedule.
Standard: 9 months + 15–18 months. Low measles transmission: 12–15 months + second dose according to national schedule.
Standard: 9 months + 15–18 months. Low measles transmission: 12–15 months + second dose according to national schedule.
Standard: 9 months + 15–18 months. Low measles transmission: 12–15 months + second dose according to national schedule.
Standard: 12–18 months + second dose ≥1 month later. Ongoing measles transmission: 9 months + 15–18 months.
Standard: 12–18 months + second dose ≥1 month later. Ongoing measles transmission: 9 months + 15–18 months.
Standard: 12–18 months + second dose ≥1 month later. Ongoing measles transmission: 9 months + 15–18 months.
Standard: 12–18 months + second dose ≥1 month later. Ongoing measles transmission: 9 months + 15–18 months.
Standard: 12–18 months + second dose ≥1 month later. Ongoing measles transmission: 9 months + 15–18 months.
Standard: 12–18 months + second dose ≥1 month later. Ongoing measles transmission: 9 months + 15–18 months.
Standard: 12–18 months + second dose ≥1 month later. Ongoing measles transmission: 9 months + 15–18 months.
Standard: 12–18 months + second dose ≥1 month later. Ongoing measles transmission: 9 months + 15–18 months.
Standard: 12–18 months + second dose ≥1 month later. Ongoing measles transmission: 9 months + 15–18 months.
Standard: 9 months + 15–18 months. Low measles transmission: 12–15 months + second dose according to national schedule.
Standard: 9 months + 15–18 months. Low measles transmission: 12–15 months + second dose according to national schedule.
Standard: 9 months + 15–18 months. Low measles transmission: 12–15 months + second dose according to national schedule.
Standard: 9 months + 15–18 months. Low measles transmission: 12–15 months + second dose according to national schedule.
Standard: 9 months + 15–18 months. Low measles transmission: 12–15 months + second dose according to national schedule.
Standard: 9 months + 15–18 months. Low measles transmission: 12–15 months + second dose according to national schedule.
Standard: 9 months + 15–18 months. Low measles transmission: 12–15 months + second dose according to national schedule.
Standard: 9 months + 15–18 months. Low measles transmission: 12–15 months + second dose according to national schedule.
Standard: 9 months + 15–18 months. Low measles transmission: 12–15 months + second dose according to national schedule.
Standard: 9 months + 15–18 months. Low measles transmission: 12–15 months + second dose according to national schedule.
Standard: 9 months + 15–18 months. Low measles transmission: 12–15 months + second dose according to national schedule.
Internationally available measles vaccines may be used interchangeably in immunization programmes.
Interchangeable with other monovalent measles vaccines for catch-up or outbreak responses
Interchangeable with other monovalent measles vaccines or followed later by a combination MR or MMR
Interchangeable with other monovalent measles vaccines or followed later by a combination MR or MMR
Interchangeable with other AIK-C or Schwarz-strain based measles vaccines
Interchangeable with other global live-attenuated measles vaccines
Interchangeable with other global live-attenuated measles vaccines
Interchangeable with other global live-attenuated measles vaccines
No information provided.
No information provided.
All WHO pre-qualified mumps-containing vaccines are considered safe and interchangeable for use in routine immunization programmes.
No information provided.
Official guidelines permit completing the second dose with a different approved MMR brand (such as Priorix) if the exact same product is unavailable, provided a minimum interval of at least 4 weeks is maintained after the first dose.
Monovalent vaccines (measles, mumps, or rubella) or other trivalent formulations (such as Priorix or MMR II), provided appropriate minimum intervals are respected.
Interchangeable with other international MMR brands featuring Moraten/Schwarz measles, Jeryl Lynn mumps, or RA 27/3 rubella strains.
No information provided.
No information provided.
No information provided.
No information provided.
No information provided.
No information provided.
No information provided.
No information provided.
No information provided.
Can be interchanged with any other MR vaccines.
Interchangeable with other global vaccines utilizing the AIK-C measles strain or the Wistar RA 27/3 rubella strain counterparts.
Interchangeable with other global combined MR or MMR vaccines utilizing standard attenuated strains.
Interchangeable with other MR formulations that utilize identical Edmonston-Zagreb or Schwarz strains.
None routinely recommended.
None routinely recommended.
None routinely recommended.
None routinely recommended.
None routinely recommended.
None routinely recommended.
None routinely recommended.
None routinely recommended.
None routinely recommended.
None routinely recommended.
None routinely recommended.
None routinely recommended.
None routinely recommended.
None routinely recommended.
None routinely recommended.
None routinely recommended.
None routinely recommended.
None routinely recommended.
None routinely recommended.
None routinely recommended.
None routinely recommended.
None routinely recommended.
None routinely recommended.
None routinely recommended.
None routinely recommended.
None routinely recommended.
None routinely recommended.
None routinely recommended.
Generally, well-tolerated
Generally, well-tolerated
Generally, well-tolerated
Generally, well-tolerated
Generally, well-tolerated
Generally, well-tolerated
Generally, well-tolerated
Generally, well-tolerated
Generally, well tolerated
Generally, well tolerated
Generally, well tolerated
Generally, well tolerated
Generally, well tolerated
Generally, well tolerated
Generally, well tolerated
Generally, well tolerated
Generally, well tolerated
Generally, well tolerated
Generally, well tolerated
Generally, well tolerated
Generally, well tolerated
Generally, well tolerated
Generally, well tolerated
Generally, well tolerated
Generally, well tolerated
Generally, well tolerated; contraindicated during pregnancy
Generally, well tolerated
Generally, well tolerated
Yes
No
No
Yes
No
Yes
No
No
No
No
No
No
No
No
No
No
No
Yes
Yes
No
No
No
No
No
No
No
No
No
Detailed pricing information for UNICEF can be found at: https://www.unicef.org/supply/documents/measles-vaccine-price-data.
Detailed pricing information for PAHO procurement can be found at: https://www.paho.org/en/documents/revolving-fund-vaccine-prices-2026 .
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at:
Detailed pricing information for UNICEF can be found at: https://www.unicef.org/supply/documents/measles-vaccine-price-data.
Detailed pricing information for PAHO procurement can be found at: https://www.paho.org/en/documents/revolving-fund-vaccine-prices-2026 .
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at:
Detailed pricing information for UNICEF can be found at: https://www.unicef.org/supply/documents/measles-vaccine-price-data.
Detailed pricing information for PAHO procurement can be found at: https://www.paho.org/en/documents/revolving-fund-vaccine-prices-2026 .
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at:
Detailed pricing information for UNICEF can be found at: https://www.unicef.org/supply/documents/measles-vaccine-price-data.
Detailed pricing information for PAHO procurement can be found at: https://www.paho.org/en/documents/revolving-fund-vaccine-prices-2026 .
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at:
Detailed pricing information for UNICEF can be found at: https://www.unicef.org/supply/documents/measles-vaccine-price-data.
Detailed pricing information for PAHO procurement can be found at: https://www.paho.org/en/documents/revolving-fund-vaccine-prices-2026 .
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at:
Detailed pricing information for UNICEF can be found at: https://www.unicef.org/supply/documents/measles-vaccine-price-data.
Detailed pricing information for PAHO procurement can be found at: https://www.paho.org/en/documents/revolving-fund-vaccine-prices-2026 .
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at:
Detailed pricing information for UNICEF can be found at: https://www.unicef.org/supply/documents/measles-vaccine-price-data.
Detailed pricing information for PAHO procurement can be found at: https://www.paho.org/en/documents/revolving-fund-vaccine-prices-2026 .
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at:
Detailed pricing information for UNICEF can be found at: https://www.unicef.org/supply/documents/measles-vaccine-price-data.
Detailed pricing information for PAHO procurement can be found at: https://www.paho.org/en/documents/revolving-fund-vaccine-prices-2026 .
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at:
Detailed pricing information for UNICEF procurement can be found at: https://www.unicef.org/supply/documents/measles-mumps-and-rubella-vacci…
Detailed pricing information for PAHO procurement can be found at: https://www.paho.org/en/documents/vaccine-prices-revolving-fund-2026
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at: https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine…
Detailed pricing information for UNICEF procurement can be found at: https://www.unicef.org/supply/documents/measles-mumps-and-rubella-vacci…
Detailed pricing information for PAHO procurement can be found at: https://www.paho.org/en/documents/vaccine-prices-revolving-fund-2026
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at: https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine…
Detailed pricing information for UNICEF procurement can be found at: https://www.unicef.org/supply/documents/measles-mumps-and-rubella-vacci…
Detailed pricing information for PAHO procurement can be found at: https://www.paho.org/en/documents/vaccine-prices-revolving-fund-2026
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at: https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine…
Detailed pricing information for UNICEF procurement can be found at: https://www.unicef.org/supply/documents/measles-mumps-and-rubella-vacci…
Detailed pricing information for PAHO procurement can be found at: https://www.paho.org/en/documents/vaccine-prices-revolving-fund-2026
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at: https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine…
Detailed pricing information for UNICEF procurement can be found at: https://www.unicef.org/supply/documents/measles-mumps-and-rubella-vacci…
Detailed pricing information for PAHO procurement can be found at: https://www.paho.org/en/documents/vaccine-prices-revolving-fund-2026
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at: https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine…
Detailed pricing information for UNICEF procurement can be found at: https://www.unicef.org/supply/documents/measles-mumps-and-rubella-vacci…
Detailed pricing information for PAHO procurement can be found at: https://www.paho.org/en/documents/vaccine-prices-revolving-fund-2026
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at: https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine…
Detailed pricing information for UNICEF procurement can be found at: https://www.unicef.org/supply/documents/measles-mumps-and-rubella-vacci…
Detailed pricing information for PAHO procurement can be found at: https://www.paho.org/en/documents/vaccine-prices-revolving-fund-2026
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at: https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine…
Detailed pricing information for UNICEF procurement can be found at: https://www.unicef.org/supply/documents/measles-mumps-and-rubella-vacci…
Detailed pricing information for PAHO procurement can be found at: https://www.paho.org/en/documents/vaccine-prices-revolving-fund-2026
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at: https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine…
Detailed pricing information for UNICEF procurement can be found at: https://www.unicef.org/supply/documents/measles-mumps-and-rubella-vacci…
Detailed pricing information for PAHO procurement can be found at: https://www.paho.org/en/documents/vaccine-prices-revolving-fund-2026
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at: https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine…
Detailed pricing information for UNICEF procurement can be found at: https://www.unicef.org/supply/documents/measles-and-rubella-vaccine-mr-…
Detailed pricing information for PAHO procurement can be found at: https://www.paho.org/en/documents/revolving-fund-vaccine-prices-2026
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at: https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine-access/mi4a/mi4a-vaccine-purchase-data
Detailed pricing information for UNICEF procurement can be found at: https://www.unicef.org/supply/documents/measles-and-rubella-vaccine-mr-…
Detailed pricing information for PAHO procurement can be found at: https://www.paho.org/en/documents/revolving-fund-vaccine-prices-2026
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at: https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine-access/mi4a/mi4a-vaccine-purchase-data
Detailed pricing information for UNICEF procurement can be found at: https://www.unicef.org/supply/documents/measles-and-rubella-vaccine-mr-…
Detailed pricing information for PAHO procurement can be found at: https://www.paho.org/en/documents/revolving-fund-vaccine-prices-2026
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at: https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine-access/mi4a/mi4a-vaccine-purchase-data
Detailed pricing information for UNICEF procurement can be found at: https://www.unicef.org/supply/documents/measles-and-rubella-vaccine-mr-…
Detailed pricing information for PAHO procurement can be found at: https://www.paho.org/en/documents/revolving-fund-vaccine-prices-2026
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at: https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine-access/mi4a/mi4a-vaccine-purchase-data
Detailed pricing information for UNICEF procurement can be found at: https://www.unicef.org/supply/documents/measles-and-rubella-vaccine-mr-…
Detailed pricing information for PAHO procurement can be found at: https://www.paho.org/en/documents/revolving-fund-vaccine-prices-2026
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at: https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine-access/mi4a/mi4a-vaccine-purchase-data
Detailed pricing information for UNICEF procurement can be found at: https://www.unicef.org/supply/documents/measles-and-rubella-vaccine-mr-…
Detailed pricing information for PAHO procurement can be found at: https://www.paho.org/en/documents/vaccine-prices-revolving-fund-2026
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at
https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine…
Detailed pricing information for UNICEF procurement can be found at: https://www.unicef.org/supply/documents/measles-and-rubella-vaccine-mr-…
Detailed pricing information for PAHO procurement can be found at: https://www.paho.org/en/documents/vaccine-prices-revolving-fund-2026
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at
https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine…
Detailed pricing information for UNICEF procurement can be found at: https://www.unicef.org/supply/documents/measles-and-rubella-vaccine-mr-…
Detailed pricing information for PAHO procurement can be found at: https://www.paho.org/en/documents/vaccine-prices-revolving-fund-2026
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at
https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine…
Detailed pricing information for UNICEF procurement can be found at: https://www.unicef.org/supply/documents/measles-and-rubella-vaccine-mr-…
Detailed pricing information for PAHO procurement can be found at: https://www.paho.org/en/documents/vaccine-prices-revolving-fund-2026
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at
https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine…
Detailed pricing information for UNICEF procurement can be found at: https://www.unicef.org/supply/documents/measles-and-rubella-vaccine-mr-…
Detailed pricing information for PAHO procurement can be found at: https://www.paho.org/en/documents/vaccine-prices-revolving-fund-2026
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at
https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine…
Detailed pricing information for UNICEF procurement can be found at: https://www.unicef.org/supply/documents/measles-and-rubella-vaccine-mr-…
Detailed pricing information for PAHO procurement can be found at: https://www.paho.org/en/documents/vaccine-prices-revolving-fund-2026
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at
https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine…
World Health Organization. Measles vaccine (Live), 5-dose vial. WHO Prequalification of Medical Products. Geneva: World Health Organization; 2026. (https://extranet.who.int/prequal/vaccines/p/measles-vaccine-live ,accessed 25 September 2026).
World Health Organization. Measles vaccine (Live), 10-dose vial. WHO Prequalification of Medical Products. Geneva: World Health Organization; 2026. (https://extranet.who.int/prequal/vaccines/p/measles-vaccine-live-0, accessed 25 September 2026).
Biological E. Limited. Measles Vaccine (Live) [package insert]. Hyderabad: Biological E. Limited; 2026. (https://extranet.who.int/prequal/sites/default/files/vwa_vaccine/FVP-P-…, accessed 25 September 2026).
Central Drugs Standard Control Organisation. Minutes of the Meeting of Subject Expert Committee (SEC) – Vaccine to review proposals and advise Drugs Controller General (India) in matters for Biologicals & PAC proposals held on 2 July 2021. New Delhi: Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India; 2021. (https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadCommit…, accessed 25 September 2026).
World Health Organization. Measles vaccines: WHO position paper – April 2017. Wkly Epidemiol Rec. 2017;92(17):205–27. (https://www.who.int/publications/i/item/who-wer9217-205-227, accessed 1 August 2026).
NPO Microgen. Live tissue culture measles vaccine. Moscow: NPO Microgen; (https://microgen.ru/en/products/vaktsiny/vaktsina-korevaya-kulturalnaya-zhivaya/, accessed 21 August 2026).
ICU & ED. Vắc xin MVVAC [MVVAC vaccine]. 2023 Dec 28. (https://hscc.vn/tools.asp?id=bantin&idnhom=7&idtin=1333, accessed 21 August 2026).
World Health Organization. WHO Prequalification of Vaccines database: Prequalified vaccines. Geneva: World Health Organization; 2026. (https://extranet.who.int/prequal/vaccines/prequalified-vaccines ,accessed 22 August 2026).
Shafyi A, Mohammadi A. Measles Vaccines in Iran: A 50-Year Review of Vaccine Development, Production and Effectiveness (1967 - 2017). Jundishapur J Microbiol. 2018;11(5):e60725. doi: 10.5812/jjm.60725.
World Health Organization. WHO Prequalification of Vaccines database: Prequalified vaccines. Geneva: World Health Organization; 2026. (https://extranet.who.int/prequal/vaccines/prequalified-vaccines ,accessed 22 August 2026).
Ueda S. Development of measles vaccines in Japan. Vaccine. 2009 May 21;27(24):3230-1. doi: 10.1016/j.vaccine.2009.02.066. Epub 2009 Feb 28. PMID: 19446197.
Pharmaceuticals and Medical Devices Agency (PMDA). Pharmaceuticals and medical devices safety information. Tokyo: PMDA; 2006. Report No.: 221. (pmda.go.jp, accessed 22 August 2026)
Kyoto Encyclopedia of Genes and Genomes (KEGG). KEGG DRUG: Freeze-dried live attenuated measles vaccine. Kyoto: Kanehisa Laboratories; January 2026. Entry D04866. (https://www.genome.jp/entry/D04866, accessed 22 August 2026).
Zydus Lifesciences Limited. Measles Vaccine (Live) I.P. (Freeze Dried): summary of product characteristics. New Delhi: Central Drugs Standard Control Organization; 2024. (https://www.cdsco.gov.in/opencms/opencms/en/biologicals/Vaccines, accessed 23 August 2026).
1. Beijing Institute of Biological Products Co., Ltd. Measles, mumps and rubella combined vaccine, live: package insert. Beijing: Beijing Institute of Biological Products Co., Ltd.; 2026. (, accessed 24 August 2026).
2. Beijing Institute of Biological Products Co., Ltd. Measles, mumps and rubella combined vaccine, live. Beijing: Beijing Institute of Biological Products Co., Ltd.;
(https://www.bjbpi.com/Product-Center, accessed 24 August 2026).
1. Fundação Oswaldo Cruz (Fiocruz), Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos). Measles, mumps and rubella vaccine (attenuated): prescribing information for healthcare professionals. Rio de Janeiro: Bio-Manguinhos/Fiocruz; 2022. (, accessed 24 August 2026)
1. World Health Organization. WHO Prequalification of Vaccines database: Prequalified vaccines. Geneva: World Health Organization; 2026. https://extranet.who.int/prequal/vaccines/prequalified-vaccines( ,accessed 04 August 2026)
2. Central Drugs Standard Control Organization. Permission to manufacture a new drug for sale or to distribute: TRESIVAC (Live, Attenuated, Freeze-Dried Measles, Mumps, and Rubella Vaccine), Manufacturing Licence No. 10 (Form 28-D). New Delhi: Ministry of Health and Family Welfare, Government of India; 2000 July 18 (Renewed 2020 August 27).
1. World Health Organization. WHO Prequalification of Vaccines database: Prequalified vaccines. Geneva: World Health Organization; 2026. https://extranet.who.int/prequal/vaccines/prequalified-vaccines(,accessed 04 August 2026)
2. Federal Agency for Medicines and Health Products (FAMHP). [Summary of product characteristics: Priorix powder and solvent for solution for injection in a pre-filled syringe (measles, mumps and rubella vaccine, live)](https://gsk.com). Brussels: FAMHP; 1997 May 20 (amended 1997 December 4).
1. World Health Organization. WHO Prequalification of Vaccines database: Prequalified vaccines. Geneva: World Health Organization; 2026. https://extranet.who.int/prequal/vaccines/prequalified-vaccines(,accessed 04 August 2026)
2. European Medicines Agency. M-M-RVAXPRO. Amsterdam: European Medicines Agency. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/m-m-rvaxpro (accessed 4 August 2026).
3. Krow-Lucal E, Marin M, Shepersky L, Bahta L, Loehr J, Dooling K. Measles, mumps, rubella vaccine (PRIORIX): recommendations of the Advisory Committee on Immunization Practices—United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(46):1465–1470. ( https://www.cdc.gov/mmwr/volumes/71/wr/mm7146a1.htm, accessed 4 August 2026).
1. Rostec State Corporation. Vactrivir combined measles, rubella, parotitis live vaccine. Moscow: Rostec State Corporation; (https://rostec.ru/en/directions/healthcare/products-projects/vaktrivir-…, accessed 21 August 2026).
1. Shahkarami MK, Mokhtari Azad T, Aghaiypour K, Shafyi A, Taqavian M, Mohammadi A. Establishment of a standard seed lot system of an Iranian Mumps virus strain; RS-12, for mass production of mumps and MMR vaccines. Iran Red Crescent Med J. 2012 Sep;14(9):508-14. Epub 2012 Sep 30. PMID: 23115712; PMCID: PMC3482322.
2. Sajadi SM, Shafyi A, Mohammadi A, Gholami MA. Stability study of Measles AIK-C strain, Mumps RS-12 strain and Rubella Takahashi strain in live attenuated MMR vaccine. Archives of Razi Institute. 2004;58(1):25-33.
1. Shanghai Institute of Biological Products Co., Ltd. Measles, mumps and rubella combined vaccine, live. Shanghai: Shanghai Institute of Biological Products Co., Ltd.; (https://www.siobp.com/Web/Page?_pid=article&aid=6e715f63-54d6-44fb-a22d…, accessed 24 August 2026).
2. Hainan Medical Products Administration. Measles, mumps and rubella combined vaccine, live: vaccine registration information. Haikou: Hainan Medical Products Administration; 2026. (https://amr.hainan.gov.cn/himpa/xxgk/gsgg/ymbagg/202601/t20260115_40116…, accessed 24 August 2026).
1. Zydus Lifesciences Limited. Measles, Mumps and Rubella Vaccine (Live) I.P. (Freeze Dried) (ZyVac® MMR): summary of product characteristics. New Delhi: Central Drugs Standard Control Organization; 2024. (https://www.cdsco.gov.in/opencms/opencms/en/biologicals/Vaccines, accessed 23 August 2026).
1. World Health Organization. WHO Prequalification of Vaccines database: Prequalified vaccines. Geneva: World Health Organization; 2026. https://extranet.who.int/prequal/vaccines/prequalified-vaccines(, accessed 04 August 2026)
2. Central Drugs Standard Control Organization. Permission to manufacture a new drug for sale or to distribute: Measles and Rubella Vaccine (Live), I.P. (Attenuated, Freeze Dried), Permission No. MF-190/2017. New Delhi: Ministry of Health and Family Welfare, Government of India; 2017 August 16.
1. World Health Organization. WHO Prequalification of Vaccines database: Prequalified vaccines. Geneva: World Health Organization; 2026. https://extranet.who.int/prequal/vaccines/prequalified-vaccines (, accessed 04 August 2026)
2. Central Drugs Standard Control Organization. Permission to manufacture a new drug for sale or to distribute: MR-VAC (Live, Attenuated, Freeze-Dried Measles and Rubella Vaccine), Permission No. MF/BIO/20/000065 (Form 46). New Delhi: Ministry of Health and Family Welfare, Government of India; 1989 April 13.
1. Beijing Institute of Biological Products Co., Ltd. Measles and rubella combined vaccine, live: package insert. Beijing: Beijing Institute of Biological Products Co., Ltd.;(https://www.bjbpi.com/Product-Center/, accessed 23 August
1. Beijing Minhai Biotechnology Co., Ltd. Measles and rubella combined vaccine, live. Beijing: Beijing Minhai Biotechnology Co., Ltd.;(https://www.biominhai.com/product/13.html, accessed 23 August
1. Brazilian Health Regulatory Agency (ANVISA). Measles and rubella vaccine (attenuated): new registration. Brasília: ANVISA; 2022(https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/novos-medicamento…, accessed 23 August
2. Paraná State Department of Health. Technical note: zero dose against measles. Curitiba: Paraná State Department of Health; 2025(https://www.saude.pr.gov.br/sites/default/arquivos_restritos/files/docu…, accessed 23 August).
3. Espírito Santo State Department of Health. Technical Note No. 51/2025: measles-rubella vaccine, Oswaldo Cruz Foundation (Fiocruz). Vitória: Espírito Santo State Department of Health; 2025 (https://saude.es.gov.br/Media/Imuniza%C3%A7%C3%A3o/nota-tecnica/NOTA_T%…, accessed 23 August 2026).
1. Pharmaceuticals and Medical Devices Agency. MEARUBIK: prescribing information. Tokyo: Pharmaceuticals and Medical Devices Agency; 2026.
(https://www.pmda.go.jp/PmdaSearch/iyakuDetail/630144_636940CD1029_1_32#…, accessed 24 August 2026).
1. Pharmaceuticals and Medical Devices Agency. Freeze-dried live attenuated measles, rubella combined vaccine “DAIICHI SANKYO”: prescribing information. Tokyo: Pharmaceuticals and Medical Devices Agency; 2025. (https://www.pmda.go.jp/PmdaSearch/iyakuDetail/430574_636940CD3048_1_07#…, accessed 24 August 2026).
1. Center for Research and Production of Vaccines and Biologicals (POLYVAC). Measles-Rubella Combination Vaccine (MRVAC). Hanoi: POLYVAC; (https://polyvac.com.vn/en/service/pathology-testing/, accessed 21 August 2026).
1. Shafyi A, Mohammadi A. Measles Vaccines in Iran: A 50-Year Review of Vaccine Development, Production and Effectiveness (1967 - 2017). Jundishapur J Microbiol. 2018;11(5):e60725. doi: https://doi.org/10.5812/jjm.60725
1. Pharmaceuticals and Medical Devices Agency (PMDA). Pharmaceuticals and medical devices safety information. Tokyo: PMDA; 2006. Report No.: 221. Available from: pmda.go.jp
2. Kyoto Encyclopedia of Genes and Genomes (KEGG). KEGG DRUG: Freeze-dried live attenuated measles-rubella combined vaccine. Kyoto: Kanehisa Laboratories; January 2026 . Entry D08804. ( https://www.genome.jp/entry/D08804, accessed 22 August, 2026)
3. Tanaka-Taya K, Sunagawa T, Morino S, Kanai M, Takahashi T, Sugawara T, et al. Progress toward measles elimination in Japan. Vaccine. 2018;36(52):8039-8045.
1. Zydus Lifesciences Limited. Measles and Rubella Vaccine (Live) I.P. (Freeze Dried): summary of product characteristics. New Delhi: Central Drugs Standard Control Organization; 2024. (https://www.cdsco.gov.in/opencms/opencms/en/biologicals/Vaccines, accessed 23 August 2026).
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
